ASH 2022 | Phase II study investigating the efficacy of daratumumab in patients with stage 3B AL amyloidosis
Efstathios Kastritis
• 11 Dec 2022
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, outlines early results from a Phase II study evaluating the safety and efficacy of daratumumab monotherapy in newly diagnosed patients with stage 3B light chain (AL) amyloidosis (NCT04131309). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Honoraria; Pfizer: Honoraria, Research Funding; GSK: Honoraria; Genesis Pharma: Honoraria; Janssen: Honoraria, Research Funding; Amgen: Honoraria, Research Funding.
